2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Pathology, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Bleeding and Clotting, Bleeding Disorders, Thromboembolism, Thrombotic Disorders, VWD, Immunology, Autoimmune Disorders, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

1305 Pharmacologic inhibition of the apelin receptor (APJ) with TX1351 suppresses angiodysplasia and arteriovenous shunt formation in von Willebrand Factor–Deficient mice

Xiaofei Li, PhD, Jaime Darce, PhD2, Peter Marek, PhD3, Sanjana Hemdev, MS4, Hitesh Soni, PhD, MBA5, Arthur Marivin, PhD6, Anthony J. Muslin, MD7, John Diener, PhD8, Peter McNamara, PhD9
1 Tectonic Therapeutic Inc., Watertown, Massachusetts, United States
2 Tectonic Therapeutic Inc., Watertown, Massachusetts, United States
3 Tectonic Therapeutic Inc., Watertown, Massachusetts, United States
4 Tectonic Therapeutic Inc., Watertown, Massachusetts, United States
5 Tectonic Therapeutic Inc., Watertown, Massachusetts, United States
6 Tectonic Therapeutic Inc., Watertown, Massachusetts, United States
7 Tectonic Therapeutic Inc., Watertown, Massachusetts, United States
8 Tectonic Therapeutic Inc., Watertown, Massachusetts, United States
9 Tectonic Therapeutic Inc., Watertown, Massachusetts, United States

Introduction: von Willebrand disease (vWD) is the most common inherited bleeding disorder, with an estimated prevalence of ~1 in 1,000 individuals. In Type 2A vWD, mutations in the A2 domain of von Willebrand factor (vWF) render vWF hypersensitive to ADAMTS-13 cleavage or impair multimer assembly and secretion, resulting in loss of plasma high-molecular-weight multimers (HMWMs). Acquired von Willebrand syndrome (AvWS) phenocopies Type 2A vWD, as high-shear states arising from calcific aortic stenosis (Heyde syndrome) or left ventricular assist devices (LVADs) drive excessive ADAMTS-13-mediated cleavage of HMWMs. Loss of vWF HMWMs promotes endothelial proliferation, migration, junctional destabilization, and angiogenesis via enhanced VEGF/VEGFR2 and Ang2/Tie2 signaling, thereby causing angiodysplasia, arteriovenous malformations (AVMs), and mucocutaneous and gastrointestinal (GI) bleeding. vWF knockdown in HUVECs and blood outgrowth endothelial cells, as well as vWF-knockout (KO) mice, support an inhibitory role for vWF in angiogenesis. We previously demonstrated in mice that the apelin (Apln)/APJ (Aplnr) axis is an important regulator of angiogenesis, AVM formation, and bleeding in hereditary hemorrhagic telangiectasia (HHT). Here, we investigated whether apelin/APJ signaling is enhanced upon loss of vWF and evaluated whether pharmacologic apelin/APJ inhibition, suppresses angiogenesis, angiodysplasia, and arteriovenous (AV) shunt formation in vivo.
Methods: TX1351 is a potent, selective anti-mouse APJ antagonist (humanized VHH-Fc) generated using Tectonic's GEODe™ platform. TX1351 suppression of apelin-mediated cAMP, p-AKT, and p-ERK responses was determined in vitro in in CHO cells stably expressing mouse APJ; its ability to inhibit retinal vascular outgrowth was determined in vivo in C57BL/6 neonatal mice. vWF KO mice, which lack all vWF multimers, including HMWMs, were used to assess the vascular consequences of vWF loss. Apln transcript was quantified by RT-qPCR in ear tissue of 8-week-old vWF KO versus wild-type (WT) mice. To evaluate APJ antagonism, vWF KO cohorts received TX1351 or isotype control VHH-Fc (10 mg/kg, twice weekly, intraperitoneally) beginning at 3 weeks of age (5 weeks of dosing) or 5 weeks of age (3 weeks of dosing), while WT mice received isotype control treatment from 3 weeks (served as no disease control); all mice were sacrificed at 8 weeks for vascular assessment. AV shunting in the GI tract was assessed by intracardiac blue latex-dye perfusion via the left ventricle, and vascular density was quantified by anti-CD31 immunofluorescence in ears with or without ear-punch injury (n = 8 -15, one-way ANOVA with Tukey’s multiple comparisons).
Results: TX1351 potently inhibited apelin-mediated cAMP, p-AKT, and p-ERK signaling in vitro. In neonatal mice, single dose of TX1351 inhibited retinal vascular outgrowth by 16% at P6. Apln mRNA was significantly upregulated (1.6-fold, p = 0.015, unpaired two-tailed student t-test) in the ear tissue of vWF KO mice compared with WT controls. Consistent with the established role of vWF in restraining angiogenesis, vWF KO mice showed increased vascular density in the ear. TX1351 significantly reduced this vascular density (back to WT control level), demonstrating that APJ antagonism suppresses constitutive angiogenesis in vWF KO mice. Latex-dye perfusion of the GI vasculature in WT mice remained confined to the arterial circulation, indicating intact capillary beds; in age-matched vWF KO mice, dye filled both arterial and venous branches, indicating AV shunting, and the GI tract exhibited marked hypervascularization. TX1351 reduced the proportion of mice with detectable AV shunting from 87% to 14% and markedly decreased GI hypervascularization. The cohort treated from 3 weeks of age, which also received the longest exposure, showed the greatest reduction.
Conclusion: Loss of vWF HMWMs dysregulates angiogenesis and results in angiodysplasia and AV shunt formation in mice, and pharmacologic APJ antagonism robustly suppresses both vascular proliferation and shunting. To our knowledge, this is the first evidence implicating APJ signaling in the pathophysiology of vWD, with potential relevance to AvWS. These studies highlight the therapeutic potential of antagonizing APJ to ameliorate angiodysplasias mediated by subtypes of vWD (associated with significant loss of HMWMs) and AvWS.

Xiaofei Li, PhD: No relevant conflicts of interest to declare.